tradingkey.logo

Allurion Technologies Inc

ALUR
查看詳細走勢圖
1.405USD
-0.095-6.33%
收盤 12/19, 16:00美東報價延遲15分鐘
10.91M總市值
虧損本益比TTM

Allurion Technologies Inc

1.405
-0.095-6.33%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-6.33%

5天

-15.87%

1月

+11.51%

6月

-39.44%

今年開始到現在

-86.93%

1年

-83.85%

查看詳細走勢圖

TradingKey Allurion Technologies Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Allurion Technologies Inc當前公司基本面數據相對健康,增長潛力穩定。當前估值合理,在軟體與IT服務行業排名193/482位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.50。中期看,股價處於下降通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Allurion Technologies Inc評分

相關信息

行業排名
193 / 482
全市場排名
306 / 4582
所屬行業
軟體與IT服務

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
5.500
目標均價
+227.38%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Allurion Technologies Inc亮點

亮點風險
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
業績增長期
公司處於發展階段,最新年度總收入32.11M美元
估值高估
公司最新PE估值-0.01,處於3年歷史高位
機構加倉
最新機構持股6.53M股,環比增加33.90%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉56.18K股

Allurion Technologies Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Allurion Technologies Inc簡介

Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
公司代碼ALUR
公司Allurion Technologies Inc
CEOGaur (Shantanu)
網址https://www.allurion.com/en

常見問題

Allurion Technologies Inc(ALUR)的當前股價是多少?

Allurion Technologies Inc(ALUR)的當前股價是 1.405。

Allurion Technologies Inc 的股票代碼是什麼?

Allurion Technologies Inc的股票代碼是ALUR。

Allurion Technologies Inc股票的52週最高點是多少?

Allurion Technologies Inc股票的52週最高點是16.810。

Allurion Technologies Inc股票的52週最低點是多少?

Allurion Technologies Inc股票的52週最低點是1.020。

Allurion Technologies Inc的市值是多少?

Allurion Technologies Inc的市值是10.91M。

Allurion Technologies Inc的淨利潤是多少?

Allurion Technologies Inc的淨利潤為-26.15M。

現在Allurion Technologies Inc(ALUR)的股票是買入、持有還是賣出?

根據分析師評級,Allurion Technologies Inc(ALUR)的總體評級為買入,目標價格為5.500。

Allurion Technologies Inc(ALUR)股票的每股收益(EPS TTM)是多少

Allurion Technologies Inc(ALUR)股票的每股收益(EPS TTM)是-295.460。
KeyAI